↓ Skip to main content

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#47 of 2,329)
  • High Attention Score compared to outputs of the same age (97th percentile)

Mentioned by

news
11 news outlets
blogs
2 blogs
twitter
13 tweeters

Citations

dimensions_citation
349 Dimensions

Readers on

mendeley
250 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Published in
Journal for Immunotherapy of Cancer, August 2016
DOI 10.1186/s40425-016-0152-y
Pubmed ID
Authors

Lucie Heinzerling, Patrick A. Ott, F. Stephen Hodi, Aliya N. Husain, Azadeh Tajmir-Riahi, Hussein Tawbi, Matthias Pauschinger, Thomas F. Gajewski, Evan J. Lipson, Jason J. Luke

Abstract

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.

Twitter Demographics

The data shown below were collected from the profiles of 13 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 250 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 2 <1%
Brazil 1 <1%
Unknown 247 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 50 20%
Other 32 13%
Student > Ph. D. Student 25 10%
Student > Doctoral Student 23 9%
Student > Bachelor 23 9%
Other 49 20%
Unknown 48 19%
Readers by discipline Count As %
Medicine and Dentistry 119 48%
Biochemistry, Genetics and Molecular Biology 22 9%
Immunology and Microbiology 14 6%
Agricultural and Biological Sciences 10 4%
Computer Science 3 1%
Other 19 8%
Unknown 63 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 116. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2020.
All research outputs
#246,766
of 20,034,281 outputs
Outputs from Journal for Immunotherapy of Cancer
#47
of 2,329 outputs
Outputs of similar age
#5,960
of 283,466 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 20,034,281 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,329 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,466 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them